Kornimate/medical-research-clean huggingface dataset:
tamo therapy versus postural control exercise in children with congenital muscular torticollis

Conditions: Torticollis Congenital

Summary: a randomized control trial was conducted through convenient sampling. 18 subjects were randomly allocated into two groups, group a received postural control exercises in addition to conventional therapy, while group b received tamo therapy along with conventional therapy. analysis.

torticollis is common in children and can be congenital or acquired. acquired cases can result from neck muscles or bone injuries. though distressing for parents, it usually improves over time. treatment includes postural control exercise and tamo therapy, along with conventional treatment. to compare the effects of tamo therapy versus postural control exercises on children with congenital muscular torticollis on cervical range of motion. a randomized control trial was conducted through convenient sampling. eighteen subjects were randomly allocated into two groups; group a received postural control exercises in addition to conventional therapy, while group b received tamo therapy along with conventional therapy. the duration of the treatment was eight weeks. goniometer, still photography, muscle function. eighteen participants (n=18) were included in the study.

Eligibility criteria:
inclusion criteria: * greater than 3 months * both genders * abnormal neck posture * torticollis of both sides exclusion criteria: * scm mass present * deficit in cervical prom greater than 15 degree * craniosynostosis (it is a birth defect in which the bones in a baby skull join together too early) * infectious * metabolic * scoliosis of spine * developmental plagiocephaly * scm tumor * visual disorder
pd-1 inhibitor combined with progesterone treatment in fst for patients with mmrd endometrial cancer

Conditions: Endometrial Cancer; Endometrioid Carcinoma; Mismatch Repair Deficiency

Summary: the objective of this study was to investigate the feasibility of a pd-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (mmrd) endometrial cancer who wish to preserve fertility.

endometrial cancer (ec) is a prevalent gynecological cancer with an escalating global incidence. the standard treatment for endometrial cancer is total hysterectomy and bilateral salpingo-oophorectomy. however, given the rising incidence of endometrial cancer in younger individuals and the the delay in the age of human reproduction, the conservation of endometrial cancer has garnered heightened attention. clinical practice has demonstrated that high-dose progesterone can reverse the lesioned endometrium, thereby providing a rationale for the conservative treatment of early-stage endometrial cancer. pd-1 inhibitor has been utilized as a salvage treatment in many cancers including ovarian cancer, cervical cancer, lung cancer, gastric cancer and endometrial cancer. as endometrial cancer showed mmrd rates, it is assumed to be highly responsive to pd-1 inhibitor treatment. previous literature has reported that the efficacy of progesterone therapy is limited in patients with a mmrd status.here we want to investigate the feasibility of pd-1 inhibitor combined with progesterone in early stage endometrial cancer patients who want to preserve fertility.

Eligibility criteria:
inclusion criteria: * be between the ages of 18-45 years old; * stage ia (figo 2009) ; * confirmed diagnosis of endometrial adenocarcinoma g1-g2 based upon d\&c or hysteroscopy; * molecular classification of mmrd, determined by immunohistochemical (ihc) for mmr proteins and by the second generation sequencing (ngs) or microsatellite polymerase chain reaction (pcr); * with a strong desire for fertility preservation; * sign the informed consent. exclusion criteria: * stage ib(figo 2009) and above； * tumour differentiation of g3 or non-endometrioid adenocarcinoma； * complicated with any other malignancy； * contraindicated to conservative treatment or the use of pharmaceuticals. * contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.

Keywords: fertility preservation endometrioid carcinoma pd-1 inhibitor
radiofrequency ablation in treating patients who are undergoing surgery for thyroid cancer

Conditions: Head and Neck Cancer

Summary: rationale: radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. ultrasound-guided radiofrequency ablation may be effective treatment for thyroid cancer. purpose: this phase i trial is studying the side effects of radiofrequency ablation in treating patients who are undergoing surgery for thyroid cancer.

objectives: * determine the frequency of complications associated with radiofrequency ablation (rfa) in patients with low-risk papillary thyroid cancer undergoing thyroidectomy. * determine the utility of rfa as a treatment option for these patients. outline: this is a pilot study. an electrosurgical probe is placed by ultrasound guidance into the center of the thyroid tumor. patients undergo radiofrequency ablation directly to the tumor until the target temperature is reached\* for 5 minutes. patients then undergo standard thyroidectomy. note: \*takes approximately 15-30 minutes to reach target temperature. after completion of study treatment, patients are followed at day 1, between days 14-21, and then periodically as deemed necessary. projected accrual: a total of 15-40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * cytologically confirmed papillary thyroid cancer by fine needle aspiration * low-risk disease * no poorly differentiated cytology * intrathyroidal tumor * located within the anterior two-thirds of the thyroid lobe * tumor not adjacent to the trachea by neck ultrasound * tumor ≤ 1.5 cm by neck ultrasound * requires thyroidectomy * no cervical lymphadenopathy * no multicentric tumors by neck ultrasound * no evidence of lymph node metastasis patient characteristics: age * over 21 performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: stage i papillary thyroid cancer
prediction of therapeutic response to neoadjuvant chemotherapy in muscle invasive bladder cancer patients using spatial transcriptomics

Conditions: Muscle-invasive Bladder Cancer

Summary: although neoadjuvant chemotherapy in muscle-invasive bladder cancer has significantly improved oncological outcomes, approximately 50% of patients do not respond to neoadjuvant chemotherapy, which has adverse effects on patients by causing treatment toxicity and surgical delays. therefore, treatment tailored specifically to the individual patient based on the genetic and/or molecular profile of the patient is urgently needed. among patients scheduled for neoadjuvant chemotherapy, the investigators should differentiate between patients who will be highly effective with neoadjuvant chemotherapy and those who will not, and preferentially select other treatments including radical cystectomy in the patients with high probability of failure to neoadjuvant chemotherapy. however, there is no standard which patients would benefit from neoadjuvant chemotherapy. this study plans to predict treatment response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer by analyzing genetic and molecular profiles of tumor tissues obtained through transurethral bladder tumor resection.


Eligibility criteria:
inclusion criteria: * suspicious of bladder cancer scheduled to have transurethral resection of bladder tumor * consent to the provision of their biospecimen. * willing to cooperate with this study and comply with the restrictions. * voluntarily signed the consent form for participation in the study. * age ≥18. exclusion criteria: * do not agree with this study. * vulnerable participants
safety and efficacy of pf-04217329 in patients with glaucoma or elevated eye pressure.

Conditions: Primary Open-Angle Glaucoma; Ocular Hypertension

Summary: to evaluate the safety and efficacy of pf-04217329.


Eligibility criteria:
inclusion criteria: * diagnosis of primary open-angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in 1 or both eyes. * qualifying intraocular pressure (iop) in the same eye at the eligibility 1 and 2 measurements. exclusion criteria: * closed/barely open anterior chamber angle or a history of acute angle closure in either eye. * anticipate the need to initiate or modify medication (systemic or topical) that is known to affect intraocular pressure (iop) during the study period.

Keywords: open-angle glaucoma ocular hypertension
study on efficacy and safety of reparixin in the treatment of hospitalized patients with severe covid-19 pneumonia.

Conditions: Pneumonia, Viral

Summary: the study objective is to assess efficacy and safety of reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe covid-19 pneumonia.

this is a phase 3 clinical trial designed as a randomized, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of reparixin in hospitalized adult patients with severe covid-19 pneumonia. patients will be screened for the participation in the study and eventually randomized based on an unbalanced randomization scheme (2:1) to reparixin oral tablets (2 x 600 mg tid) for up to 21 days or to placebo. an unequal randomization is justified by the need to gain experience and more safety data with the investigated treatment and by an expected better acceptability of the trial by patients. the placebo control arm is justified by the unavailability of a well-defined standard of care for subjects with covid-19 pneumonia who are candidates for this study. all patient will receive the standard supportive care based on the patient's clinical need. follow-up information on the patient's clinical condition will be collected until day 90.

Eligibility criteria:
inclusion criteria: 1. age 18 to 90, male and female subject of any race 2. reverse transcriptase polymerase chain reaction (rt-pcr)-confirmed covid-19 infection based on a nasal / oropharyngeal swab within 10 days before randomization 3. at least one of the following: 1) respiratory distress with tachypnea (rr ≥ 24 breaths/min without oxygen); 2) partial arterial oxygen pressure (pao2) / fraction of inspiration o2 (fio2), p/f \>100 and \<300 mmhg (1mmhg = 0.133kpa), 3) spo2 ≤ 94% while breathing ambient air. calculation through validated sat/fio2 scales is allowed. p/f value of reference if the last available before the signature of consent. 4. need of supplemental oxygen (i.e. new use of supplemental oxygen, or increased oxygen requirement if on chronic oxygen) requiring low- or high-flow oxygen or non-invasive mechanical ventilation (7-point who-os category 4 or 5). 5. radiological chest imaging (x-rays, ct scan) confirms lung involvement and inflammation. exclusion criteria: 1. cannot obtain informed consent. 2. hepatic dysfunction with child pugh score b or c, or alt or ast\> 5 times the upper limit. 3. renal dysfunction with estimated glomerular filtration rate (mdrd) \< 50 ml/min/1.73 m2 or patient receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. bacterial sepsis (besides covid-19 sepsis). 5. known congenital or acquired immune deficiency. 6. positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study.

Keywords: covid-19 sars-cov-2 pneumonia severe pneumonia
treatment of striae distensae with fractional radiofrequency and topical tretinoin

Conditions: Striae Distensae

Summary: the study aims to explore the potential of combination therapy with fractional radiofrequency and topical tretinoin for treatment and overall improvement of striae albae. we also aim to assess subject satisfaction, local skin responses and adverse effects/reactions in relation to the treatments, alone and in combination.


Eligibility criteria:
inclusion criteria: 1. subject has provided written informed consent 2. subject is 18 years of age or older 3. fitzpatrick skin type i-iii 4. striae albae (grade ii-iv) ≥1 year of age and ≥ 4 lesions with a length of ≥ 2 cm each 5. women of childbearing potential are not pregnant (confirmed by a negative u-hcg prior to study treatments) and use a safe contraceptive method prior to treatments. exclusion criteria: 1. severe concurrent conditions such as cardiac disorders or poorly regulated diabetes 2. history of skin disorders such as keloids, abnormal wound healing or very fragile skin 3. history of heat-stimulated disease such as herpes simplex in the treatment area 4. history of bleeding coagulopathies or use of anti-coagulants 5. surgery in the treatment area past 6 months or before complete healing 6. tattoo or permanent make-up in treatment area 7. excessively tanned skin from sun, tanning bed or tanning creams last 2 weeks 8. dermabrasion, resurfacing, soft tissue/fat injections or chemical peeling in treatment area the past 3 months 9. abnormal skin (e.g. rash, infection, dermatitis) at the treatment area at the time of inclusion 10. treatment with isotretinoin within the past 6 months 11. use of non-steroidal anti-inflammatory drugs 1 week prior to treatment 12. known allergies to tretinoin or lidocaine/prilocaine 13. history of cancer including pre-malignant moles 14. impaired immune system due to immunosuppressive disease or medication 15. electronic device implant 16. any implantable metal piece or permanent chemical substance in treatment area 17. if female; lactating, pregnant or planning on becoming pregnant during the study 18. non-eligibility at the discretion of the investigator
serratus anterior plane block and transthoracic plane block in pectus surgery

Conditions: Pectus Excavatum

Summary: the most important problem in the postoperative period in patients scheduled for pectus deformity correction surgery is pain. due to the catastrophic neurological complications of thoracic epidural analgesia, the tendency towards plane blocks has been increasing in recent years. serratus plane block (sap block), performed under ultrasound guidance, is used to treat pain in thoracic surgery. however, whether it has an effect on sternum pain is still controversial and there are not enough studies. transversus thoracic plane block (ttp block) provides effective analgesia in sternotomies. for this reason, we aimed to show that the ttp block added to the sap block will provide more effective analgesia in order to provide adequate analgesia for the pressure and pain sensation of the bars placed on the sternum in pectus surgery.

the most important problem in the postoperative period in patients scheduled for pectus deformity correction surgery is pain. it is very important for patients to start active breathing exercises and mobilize early. complications develop less frequently in patients who actively breathe and mobilize early. the tolerability of the surgery by the patient and the absence of pain in the postoperative period ensure early discharge . due to the catastrophic neurological complications of thoracic epidural analgesia, the tendency towards plane blocks has been increasing in recent years. serratus plane block (sap block), performed under ultrasound guidance, is used to treat pain in thoracic surgery. however, whether it has an effect on sternum pain is still controversial and there are not enough studies. transversus thoracic plane block (ttp block) provides effective analgesia in sternotomies. for this reason, we aimed to show that the ttp block added to the sap block will provide more effective analgesia in order to provide adequate analgesia for the pressure and pain sensation of the bars placed on the sternum in pectus surgery.

Eligibility criteria:
inclusion criteria: patients who will undergo surgery due to pectus deformity all patients over the age of 15 who will be operated on due to pectus deformity exclusion criteria: * known allergy to local anesthetics, * uncooperative patient, * the patient who refuses to participate in the study, * patients under 18 years of age.

Keywords: transversus thoracic muscle plane block postoperative analgesia pectus excavatum
sympathetic activity and renal denervation

Conditions: Hypertension

Summary: primary hypothesis: catheter-based renal denervation reduces central sympathetic activation in patients with refractory hypertension. secondary hypotheses: 1. the magnitude of the individual depressor response after catheter-based renal denervation depends on the extent of sympathoinhibition. 2. both, the reduction in arterial pressure and in central sympathetic activation are sustained over time up to 24±3 months after catheter-based renal denervation. 3. catheter-based renal denervation resets the sympathetic baroreflex to lower blood pressure values.


Eligibility criteria:
inclusion criteria: * refractory hypertension (as defined by the who: poorly controlled hypertension (\>140/90 mmhg) despite adequate doses of at least three antihypertensive drugs including a diuretic) * men or women aged \>18 years * intact peroneal nerve * written informed consent exclusion criteria: * diseases, dysfunctions, or medications (such as net inhibitors) that exclude a participation in the study according to the investigator. * legal incompetence or circumstances that interfere with the patient´s ability to fully understand scope, relevance, and/or consequences of participation in this study. * people in custody * hypersensitivity to clonidine, phenylephrine, or nitroprusside-sodium * sick sinus syndrome, second or third degree av block, bradycardia \< 50 bpm (contraindication for clonidine) * endogenous depression (contraindication for clonidine)
lactated ringers vs normal saline in patients with acute pancreatitis: a bias-adjusted meta-analysis

Conditions: Acute Pancreatitis

Summary: this study aims to compare ns and lr in terms of outcomes in patients with acute pancreatitis while addressing the current methodological issues with available meta-analyses on the topic. such comparison combined with bias adjustment will assist with identifying the optimal fluid rehydration therapy in acute pancreatitis, since most of the available data is conflicted around the topic. a database search will be conducted to identify studies comparing normal saline and ringer's lactate. existing meta-analyses will be assessed. the results will be discussed in the light of their strengths and limitations and then any deficiencies will be addressed through a new synthesis as a final step of this umbrella review. the primary outcome will be sirs at 24 hours. or and 95% confidence intervals will be generated using the quality effects model. heterogeneity will be evaluated using the i2 statistic. publication bias will be assessed using the doi plot.


Eligibility criteria:
inclusion criteria: * rcts and observational studies that compared ns vs lr in ap patients. * studies reviewed must report data as effect estimates or provide raw data sufficient to calculate effect estimates. exclusion criteria: * studies involving animal studies, pediatric patient populations, and cell lines will be excluded. all studies will be reviewed in full form by each author to determine eligibility. in case of disagreement, determination of inclusion will be reached via consensus.
risperidone plus mood stabilizer in treatment of mixed mania

Conditions: Bipolar Disorder

Summary: the study aims to assess the efficacy and tolerability of risperidone added to lithium, valproate or lamotrigine in patients experiencing a manic episode with depressive or irritable features.

* the study aims to assess the efficacy and tolerability of risperidone added to lithium, valproate or lamotrigine, or any combination of the three, in patients experiencing a manic episode with depressive or irritable symptoms. * to assess the back ground and baseline features associated with response/non-response to risperidone plus mood stabilizer in patients with mania with depressive or irritable features. * to assess the symptomatic dimensions of response of risperidone added to mood stabilizers in patients with mania with depressive or irritable features.

Eligibility criteria:
inclusion criteria: * dsm iv diagnosis of bipolar disorder, currently manic, or mixed manic * ymrs score\>/= 16 * one or more of following: 1. 3 madrs depression items scoring \>/=3 2. 3 biss depression items scoring \>/=3 3. ymrs irritability and aggressive items sum score\>/=4 * taking lithium, valproate or lamotrigine at stable dose for 4 wks or longer, with adequate serum level * age 18 and over * male or female * inpatient or outpatient exclusion criteria: -

Keywords: mixed mania depression irritability
effect of acute arterial hypertension on morphine's requirements and postsurgical pain.

Conditions: Hypertensive Disease; Pain, Postoperative

Summary: the purpose of this randomized clinical trial is to evaluate the effect of acute arterial hypertension maintained during surgery on morphine's requirements in patients undergoing laparoscopic cholecystectomy

the high arterial blood pressure has been correlated with an increase in pain threshold in animal and humans. one of the explanations to this phenomenon is a baroreceptor activity and vasopressin release at the level of spinal cord dorsal horn and hypothalamus. as far as we know, there is only one study about the effect of chronic hypertension on postoperative pain and none with acute hypertension. we therefore decided to conduct a randomized controlled trial to evaluate the effect of acute hypertension on postoperative morphine's requirements.

Eligibility criteria:
inclusion criteria: * american society of anesthesiology patient classification status(asa) i-ii * between 20 and 60 years of age * programed for elective laparoscopic cholecystectomy exclusion criteria: * history of arterial hypertension * baseline blood pressure over 139/89 * use of opioids and any analgesic drug during the last 24 hours before surgery * chronic use of nonsteroidal antiinflammatory * bmi \> 34.9 * history of drug or alcohol abuse * use of medications that interfere in the central nervous system * adverse reactions to the drugs used in the study * pregnancy

Keywords: analgesia, postoperative; analgesics opioid; hyperalgesia; remifentanil; hypertension.